KMT2A and acute myeloid leukemia: Low ID2 expression has been previously associated with poor prognosis in MLL and t(8;21) AML patients, and its overexpression inhibited MLL::AF9- and RUNX1::ETO9a-driven leukemia progression and maintenance in mice [32].